News

Dr. Michael Kapusta, MD, FRSCS, Ophthalmologist, talks about advanced (proliferative) diabetic retinopathy and pars plana ...
Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...
Early poliferative diabetic retinopathy Neovascularization of the disc or elsewhere, which does not meet the high-risk characteristics High-risk proliferative diabetic retinopathy Moderate or ...
Patient with Type 2 diabetes, proliferative diabetic retinopathy, traction retinal detachment, and age-related cataracts ...
an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of ...
an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of blindness ...